Form 4: Stoke Therapeutics Director Seth Harrison Granted New Stock Options

Stoke Therapeutics, Inc. Director Seth Loring Harrison has been granted 29,747 stock options with an exercise price of $10.90, aligning his interests with shareholder value.

Summary

• Seth Loring Harrison, a Director of Stoke Therapeutics, Inc. (STOK), was granted 29,747 Director Stock Options.
• The options have an exercise price of $10.90 per share.
• The transaction date for this grant was June 3, 2025.
• Each option represents the right to buy one share of Common Stock.
• The options will vest in full on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, contingent on Mr. Harrison's continued service.
• The options have an expiration date of June 2, 2035.
• Following this transaction, Mr. Harrison directly beneficially owns 29,747 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally viewed as a positive for aligning management interests with shareholders, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance of the company and shareholder value.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

NA

Industry Context

This is a standard practice in many industries, including biotechnology, to compensate directors with equity to align their interests with shareholders.

Corporate Governance

Related Party Transactions

• The grant of 29,747 Director Stock Options to Seth Loring Harrison, a Director of Stoke Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• The stock options will vest on the earlier of June 3, 2026, or the date of the issuer's next annual meeting of stockholders, provided the reporting person continues service.

Key Dates

Recommendation

Keywords

Stoke Therapeutics, STOK, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Form 4, Seth Loring Harrison, Biotechnology, Pharmaceuticals